Different perforin expression in peripheral blood and prostate tissue in patients with benign prostatic hyperplasia and prostate cancer

Scandinavian Journal of Immunology

Volumn 74, Issue 4, 2011, Pages 368-376

  Tokmadzic V S ^a   Tomas M I ^a   Sotosek S ^b   Laskarin G ^a   Dominovic M ^a   Tulic V ^a   Dordevic G ^a   Sustic A ^a   Mrakovcic Sutic I ^a  

^a UNIVERSITY OF RIJEKA   (Croatia)

^b KBC RIJEKA   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; PERFORIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD; CANCER TISSUE; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; DENSITY GRADIENT CENTRIFUGATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; MALE; NATURAL KILLER CELL; NATURAL KILLER T CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION;

AGED; ANTIGENS, CD; CELL SEPARATION; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; PERFORIN; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS;

EID: 80052676895     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2011.02569.x     Document Type: Article

References (28)

1. Vutuc C, Schernhammer ES, Haidinger G, Waldhör T. Prostate cancer and prostate-specific antigen (PSA) screening in Austria. Wien Klin Wochenschr 2005;117:457-61.
2. Djavan B, Eckersberger E, Espinosa G et al. Complex mechanisms in prostatic inflammatory response. European Urology Supplements 2009;8:872-8.
3. Steiner GE, Djavan B, Kramer G et al. The picture of the prostatic lymphokine network is becoming increasingly complex. Rev Urol 2002;4:171-7.
4. Robert G, Descazeaud A, Nicolaïew N et al. Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis. Prostate 2009;69:1774-80.
5. Briganti A, Capitanio U, Suardi N et al. Benign prostatic hyperplasia and its aetiologies. European Urology Supplements 2009;8:865-71.
6. Sfanos KS, Bruno TC, Maris CH et al. Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res 2008;14:3254-61.
7. Jass JR, Love SB, Northover JM. A new prognostic classification of rectal cancer. Lancet 1987;1:1303-6.
8. Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava PK, Kosma VM. Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol 1997;182:318-24.
9. Nielsen HJ, Hansen U, Christensen IJ, Reimert CM, Brunner N, Moesgaard F. Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. J Pathol 1999;189:487-95.
10. Ebelt K, Babaryka G, Frankenberger B et al. Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters. Eur J Cancer 2009;45:1664-72.
11. Kasic T, Viola A. Prostate cancer-induced immunodysfunction: a lesson from organ cultures. Immunol Lett 2005;100:98-102.
12. + lymphocytic infiltrates with disturbed effector cell characteristics in the tumor microenvironment of prostate carcinoma. Prostate 2008;68:1-10.
13. Chávez-Galán L, Arenas-Del Angel MC, Zenteno E, Chávez R, Lascurain R. Cell death mechanisms induced by cytotoxic lymphocytes. Cell Mol Immunol 2009;6:15-25.
14. Smyth MJ, Ortaldo JR, Bere W, Yagita H, Okumura K, Young HA. IL-2 and IL-6 synergize to augment the pore-forming protein gene expression and cytotoxic potential of human peripheral blood T cells. J Immunol 1990;145:1159-66.
15. Barbey C, Baumgaertner P, Devevre E et al. IL-12 controls cytotoxicity of a novel subset of self-antigen-specific human CD28+ cytolytic T cells. J Immunol 2007;178:3566-74.
16. Strbo N, Laskarin G, Bogovic Crncic T et al. Short-term cytolytic mediators' expression in decidual lymphocytes is enhanced by interleukin-15. Am J Reprod Immunol 2006;55:217-25.
17. Tokmadzić VS, Tsuji Y, Bogovic T et al. IL-18 is present at the maternal-fetal interface and enhances cytotoxic activity of decidual lymphocytes. Am J Reprod Immunol 2002;48:191-200.
18. Ebert EC. Interleukin 21 up-regulates perforin-mediated cytotoxic activity of human intra-epithelial lymphocytes. Immunology 2009;127:206-15.
19. Pipkin ME, Lieberman J. Delivering the kiss of death: progress on understanding how perforin works. Curr Opin Immunol 2007;19:301-8.
20. Sotosek Tokamdzic V, Laskarin G, Mahmutefendic H et al. Expression of cytolytic protein-perforin in peripheral blood lymphocytes in severe traumatic brain injured patients. Injury 2010; doi:. In press.
21. Djavan B. The correlation between inflammation, BPH and prostate cancer. European Urology Supplements 2009;8:863-4.
22. Handisurya H, Steiner G, Stix U et al. Differential expression of interleukin-15, a proinflammatory cytokine and T-cell growth factor, and its receptor in human prostate. Prostate 2001;49:251-62.
23. Radoja S, Frey AB. Cancer-induced defective cytotoxic T lymphocyte effector function: another mechanism how antigenic tumors escape immune-mediated killing. Mol Med 2000;6:465-79.
24. Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med 2001;7:1118-22.
25. Molon B, Ugel S, Del Pozzo F et al. Improving cancer immunotherapy by preventing chemokine nitration. 9th VIMM Annual Retreat, 2010:22.
26. Takeshi U, Sadar MD, Suzuki H et al. Interleukin-4 in patients with prostate cancer. Anticancer Res 2005;25:4595-8.
27. Lee SO, Lou W, Hou M, Onate SA, Gao AC. Interleukin-4 enhances prostate-specific antigen expression by activation of the androgen receptor and Akt pathway. Oncogene 2003;22:7981-8.
28. Allavena P, Chieppa M, Monti P, Piemonti L. From pattern recognition receptor to regulator of homeostasis: the double-faced macrophage mannose receptor. Crit Rev Immunol 2004;24:179-92.